On January 25, 2019, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments to the Center for Medicare & Medicaid Services (CMS) on the proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."